Novel insights and innovations in targeting the neurohumoral system

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Peter van der Meer

Video navigation menu

Current medication to improve morbidity/mortality in HFrEF 0:00
PARADIGM-HF trial: LCZ696 compared with enalapril with respect to morbidity/mortality 0:37
ATMOSPHERE trial - aliskiren compared with enalapril 1:42
Potassium-binding drugs to lower hyperkalemia 2:19
Conclusion - cornerstone drug therapy in HFrEF and new treatment modalities 3:11

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.